Paolo A. Ascierto, MD
Half of patients with melanoma who progressed on anti–PD-1/PD-L1 therapy benefited from the combination of nivolumab (Opdivo) and the LAG-3 inhibitor relatlimab (BMS-986016), data from a dose-expansion study showed.
The safety profile of the combination was similar for the subgroup of patients with prior PD-1/PD-L1 exposure and the overall expansion cohort, Ascierto reported. Grade 3/4 adverse events were uncommon, consisting of 3 cases each of diarrhea and colitis, and 2 cases of pneumonitis.
Ascierto PA, Bono P, Bhatia S, et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma. In: Proceedings from the 2017 ESMO Congress; September 8-12, 2017; Madrid, Spain. Abstract LBA18.
... to read the full story